Related Experiment Videos
[Does abciximab improve the prognosis of diabetics after percutaneous coronary intervention?]
José María Hernández García1, Antonio Domínguez Franco, Manuel F Jiménez-Navarro
1Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain. Hemoschum@hotmail.com
Insights
Abciximab therapy may improve outcomes for diabetic patients undergoing percutaneous coronary intervention (PCI). This study found fewer adverse events, including target vessel revascularization, in diabetic patients treated with abciximab during PCI.
Area of Science:
- Cardiology
- Interventional Cardiology
- Diabetology
Background:
- Diabetic patients experience poorer outcomes following percutaneous coronary intervention (PCI) compared to non-diabetics.
- Existing research indicates a need to explore interventions that can mitigate risks in this high-risk population.
- Understanding the impact of adjunctive therapies like abciximab is crucial for optimizing PCI results in diabetics.
Purpose of the Study:
- To evaluate the efficacy of abciximab therapy in improving clinical outcomes for diabetic patients undergoing PCI.
- To assess whether abciximab administration reduces adverse events in this specific patient cohort.
- To identify specific event types that may be most affected by abciximab treatment in diabetics undergoing PCI.
Main Methods:
- Retrospective analysis of 198 diabetic patients undergoing percutaneous transluminal coronary angioplasty (PTCA) between January 1997 and January 2000.
- Comparison between a group of 73 patients treated with abciximab and a control group of 125 patients who did not receive abciximab.
- Follow-up averaged 12.6 months, with endpoints including death, non-fatal myocardial infarction, revascularization procedures, and hospital admission for unstable angina.
Main Results:
- Patients receiving abciximab had more complex clinical profiles, including higher rates of previous myocardial infarction, worse left ventricular function, and more angiographic thrombus.
- The abciximab group experienced significantly fewer overall adverse events (22% vs. 38%) compared to the non-abciximab group.
- Abciximab treatment was associated with a significant reduction in target vessel revascularization (7.2% vs. 22.7%) and hospital readmissions for unstable angina (15.9% vs. 29.1%). Multivariate analysis identified abciximab as a predictor of fewer complications.
Conclusions:
- Abciximab therapy appears to be beneficial in reducing adverse clinical events in unselected diabetic patients undergoing percutaneous coronary intervention.
- The most significant benefit observed was a reduction in target vessel revascularization.
- Abciximab may be a valuable therapeutic option for improving PCI outcomes in diabetic patients.
Introduction And Objectives:
It is known that the outcome of percutaneous coronary intervention is worse in diabetics than in non-diabetics. The aim of our study was to determine whether abciximab therapy could improve clinical outcome in an unselected diabetic population that underwent percutaneous coronary interventions.
Material And Methods:
We analyzed retrospectively 198 diabetic patients who underwent PTCA from January 1997 to January 2000. Seventy-three patients (36.7%) were treated with abciximab and the remaining 125 patients (63.3%) did not receive abciximab. The mean follow-up was 12.6 months. The events considered were death, non-fatal myocardial infarction, any revascularization procedure (including the target vessel), and hospital admission for unstable angina.
Results:
Patients who received abciximab had more frequent previous myocardial infarction (67.1 vs. 52.8%; p = 0.04), worse left ventricular function (0.53 vs. 0.59%; p = 0.02), more frequent angiographic thrombus (67.1 vs. 36.8%; p < 0.001), more complex lesions (B2/C) (76.4 vs. 55.8%; p = 0.004), and less frequent location in left anterior descending artery (34.2 vs. 60.8%; p = 0.002). The indication for PTCA in patients who received abciximab was most often related to myocardial infarction. There were no differences between the groups in sex, age and distribution of diabetes treatment. Events were more frequent in diabetics not treated with abciximab than in those who were treated with abciximab (38 vs. 22%; p < 0.037). The patients not treated with abciximab suffered more frequently target vessel revascularization (22.7 vs. 7.2%; p < 0.007). There were no significant differences in the frequency of death or non-fatal myocardial infarction, but hospital readmissions for unstable angina were significantly more frequent in diabetics not treated with abciximab (29.1 vs. 15.9%; p = 0.045). Multivariate analysis identified abciximab as a predictor of the absence of complications during follow-up (OR: 0.45; p = 0.03).
Conclusion:
Abciximab treatment seems to reduce events in unselected diabetic patients undergoing percutaneous coronary intervention, particularly target vessel revascularization.